Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. 1979

L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan

Because of an increase in the number of reports of Guillian-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16, 1976 and nationwide surveillance for GBS was begun. This surveillance uncovered a total of 1098 patients with onset of GBS from October 1, 1976, to January 31, 1977, from all 50 states, District of Columbia, and Puerto Rico. A total of 532 patients had recently received an A/New Jersey influenza vaccination prior to their onset of GBS (vaccinated cases), and 15 patients received a vaccination after their onset of GBS. Five hundred forty-three patients had not been recently vaccinated with A/New Jersey influenza vaccine and the vaccination status for 8 was unknown. Epidemiologic evidence indicated that many cases of GBS were related to vaccination. When compared to the unvaccinated population, the vaccinated population had a significantly elevated attack rate in every adult age group. The estimated attributable risk of vaccine-related GBS in the adult population was just under one case per 100,000 vaccinations. The period of increased risk was concentrated primarily within the 5-week period after vaccination, although it lasted for approximately 9 or 10 weeks.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011129 Polyradiculoneuropathy Diseases characterized by injury or dysfunction involving multiple peripheral nerves and nerve roots. The process may primarily affect myelin or nerve axons. Two of the more common demyelinating forms are acute inflammatory polyradiculopathy (GUILLAIN-BARRE SYNDROME) and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple peripheral nerves and spinal nerve roots. Autoimmune Demyelinating Disease, Peripheral,Demyelinating Autoimmune Disease, Peripheral,Demyelinating Disease, Peripheral Autoimmune,Peripheral Autoimmune Demyelinating Disease,Polyradiculoneuritis,Polyradiculoneuritides,Polyradiculoneuropathies
D004345 Drug Industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function. Industries, Pharmaceutic,Industry, Drug,Industry, Pharmaceutic,Industry, Pharmaceutical,Pharmaceutical Industry,Drug Industries,Industries, Drug,Industries, Pharmaceutical,Pharmaceutic Industries,Pharmaceutic Industry,Pharmaceutical Industries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
May 2003, Clinical immunology (Orlando, Fla.),
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
May 2009, Ugeskrift for laeger,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
March 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
January 2014, Human vaccines & immunotherapeutics,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
June 1984, American journal of epidemiology,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
April 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
January 2000, The Yale journal of biology and medicine,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
August 2016, Journal of neurovirology,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
November 2009, Revue medicale suisse,
L B Schonberger, and D J Bregman, and J Z Sullivan-Bolyai, and R A Keenlyside, and D W Ziegler, and H F Retailliau, and D L Eddins, and J A Bryan
January 1978, Family planning perspectives,
Copied contents to your clipboard!